A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients

被引:79
|
作者
Pillans, PI
Rigby, RJ
Kubler, P
Willis, C
Salm, P
Tett, SE
Taylor, PJ
机构
[1] Princess Alexandra Hosp, Dept Clin Pharmacol, Woolloongabba, Qld 4102, Australia
[2] Univ Queensland, Princess Alexandra Hosp, Dept Med, Brisbane, Qld 4102, Australia
[3] Princess Alexandra Hosp, Renal Transplantat Unit, Woolloongabba, Qld 4102, Australia
[4] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia
关键词
mycophenolic acid; cyclosporin; acute rejection; renal transplantation;
D O I
10.1016/S0009-9120(00)00196-X
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Although monitoring of cyclosporin (CsA) is standard clinical practice postrenal transplantation. mycophenolic acid (MPA) concentrations are not routinely measured. There is evidence that a relationship exists between MPA area under the concentration-time curve (AUC) and rejection. In this study, a retrospective analysis was undertaken of 27 adult renal transplant recipients. Methods: Patients received CsA and MPA therapy and had a four-point MPA AUC investigation. The relationship between MPA AUC performed in the first week after transplantation, as well as median trough cyclosporin concentrations, and clinical outcomes in the first month posttransplant were evaluated. Results: A total of 12 patients experienced biopsy proven rejection (44.4%) and 4 patients had gastrointestinal adverse events (14.8%). A statistically significant relationship was observed between the incidence of biopsy proven rejection and both MPA AUC (p = 0.02) and median trough CsA concentration (p = 0.008). No relationship between trough MPA concentration and rejection was observed (p = 0.21). Only 3 of 11 (27%) patients with an MPA AUC > 30 mg.h/L and a median trough CsA > 175 mug/L experienced acute rejection, compared with a 56% incidence of rejection for the remaining 16 patients. Patients who experienced adverse gastrointestinal events had significantly lower MPA AUC (p = 0.04), but median trough CsA concentrations were not significantly different (p = 0.24). Further, 3 of these 4 patients had rejection episodes. Conclusions: in addition to standard CsA monitoring, we propose further investigation of the use of a 4-point sampling strategy to predict MPA AUC in the first week posttransplant, which may facilitate optimization of mycophenolate mofetil dose at a rime when patients are most vulnerable to acute rejection. (C) 2001 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:77 / 81
页数:5
相关论文
共 50 条
  • [21] The influence of Saint John's wort extract on blood concentrations of cyclosporin A, tacrolimus and mycophenolic acid in renal transplant patients
    Bauer, S
    Mai, I
    Johne, A
    Stormer, E
    Budde, K
    Roots, I
    THERAPEUTIC DRUG MONITORING, 2003, 25 (04) : 511 - 511
  • [22] Adverse effects of mycophenolic acid in renal transplant recipients: gender differences
    Ana Spasić
    Aleksandra Catić-Đorđević
    Radmila Veličković-Radovanović
    Nikola Stefanović
    Predrag Džodić
    Tatjana Cvetković
    International Journal of Clinical Pharmacy, 2019, 41 : 776 - 784
  • [23] Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients
    Colom, Helena
    Lloberas, Nuria
    Andreu, Franc
    Caldes, Ana
    Torras, Joan
    Oppenheimer, Federico
    Sanchez-Plumed, Jaime
    Gentil, Miguel A.
    Kuypers, Dirk R.
    Brunet, Merce
    Ekberg, Henrik
    Grinyo, Josep M.
    KIDNEY INTERNATIONAL, 2014, 85 (06) : 1434 - 1443
  • [24] No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients
    Kagaya, H.
    Miura, M.
    Satoh, S.
    Inoue, K.
    Saito, M.
    Inoue, T.
    Habuchi, T.
    Suzuki, T.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2008, 33 (02) : 193 - 201
  • [25] Measurement of plasma mycophenolic acid in pediatric renal transplant recipients.
    McBride, JH
    Kim, S
    Reyes, A
    Rodgerson, DO
    CLINICAL CHEMISTRY, 1998, 44 : A93 - A93
  • [26] Population pharmacokinetics of mycophenolic acid and its determinants in renal transplant recipients
    van Hest, RM
    van Gelder, T
    Vulto, AG
    Mathôt, RAA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (01) : 106 - 107
  • [27] Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia
    Atcheson, BA
    Taylor, PJ
    Kirkpatrick, CMJ
    Duffull, SB
    Mudge, DW
    Pillans, PI
    Johnson, DW
    Tett, SE
    THERAPEUTIC DRUG MONITORING, 2004, 26 (03) : 284 - 286
  • [28] Time-dependent clearance of mycophenolic acid in renal transplant recipients
    van Hest, Reinier M.
    van Gelder, Teun
    Bouw, Rene
    Goggin, Timothy
    Gordon, Robert
    Mamelok, Richard D.
    Mathot, Ron A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (06) : 741 - 752
  • [29] Adverse effects of mycophenolic acid in renal transplant recipients: gender differences
    Spasic, Ana
    Catic-Dordevic, Aleksandra
    Velickovic-Radovanovic, Radmila
    Stefanovic, Nikola
    Dzodic, Predrag
    Cvetkovic, Tatjana
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (03) : 776 - 784
  • [30] Treatment of refractory acute allograft rejection with aerosolized cyclosporin in lung transplant recipients
    Keenan, RJ
    Iacono, A
    Dauber, JH
    Smaldone, GC
    Griffith, BP
    LATE GRAFT LOSS, 1997, 28 : 75 - 76